A virus designed to attack tumours is moving through human testing for pancreatic cancer. Its latest report offers a reason for further research, and a useful lesson in reading the numbers behind a promising headline.
On 30 September 2026, Nature Medicine published the randomised Phase IIb VIRAGE trial of VCN-01, also called zabilugene almadenorepvec. Researchers compared the experimental virus plus gemcitabine and nab-paclitaxel chemotherapy with that chemotherapy alone in previously untreated metastatic pancreatic ductal adenocarcinoma. “Metastatic” means the cancer has spread beyond its original site. Peer-reviewed trial report
A virus with a second job
VCN-01 is an oncolytic adenovirus—an engineered virus intended to multiply in and destroy tumour cells. It also produces hyaluronidase, an enzyme intended to break down part of the surrounding tissue barrier, or stroma. The proposed benefit is better access for other treatments and greater exposure of the tumour to immune responses. These are intended mechanisms, rather than proof of benefit in every patient. Theriva’s mechanism and development account
The virus was given intravenously. The study was open-label, meaning participants and investigators knew which treatment was administered. Phase II studies investigate activity and safety; Phase III trials generally provide larger comparisons. NCI’s guide to trial phases
The analysis group changes the strength of the result
In the paper’s intent-to-treat analysis, involving 101 participants, median overall survival was 10.6 months versus 8.6 months. The reported P value was 0.196. A separate full analysis set of 96 participants showed 10.8 versus 8.6 months, with P = 0.055. Median is the midpoint of the survival distribution, rather than a guaranteed gain for an individual. Survival analyses
The study used a prespecified two-sided statistical threshold of 0.10, making the full-analysis result sufficient under its design. The broader analysis did not cross that threshold. This explains how the trial can report an endpoint success while the overall evidence still needs confirmation. Sponsor’s SEC-filed trial-design presentation
Our interpretation is that the difference between these analyses deserves as much attention as the higher median. Statistical thresholds and the people included in an analysis affect how confidently a result can be generalised.
Safety and the next trial remain central
Specialist reporting on the paper describes fever, flu-like symptoms, raised liver enzymes and reduced platelet counts among virus-related adverse events. Platelets help blood clot. Two fatal events, one in each arm, were reported as unrelated to study treatment. Safety findings reported by Targeted Oncology
Theriva says the smaller Phase IIa VIRAGE2 study is testing more frequent dosing to inform a possible future pivotal Phase III trial. The September publication is a research result, rather than regulatory approval or evidence that pancreatic cancer has been cured. Next development stage
Featured image: Cancer-research laboratory image from the National Cancer Institute; not a photograph of VCN-01 preparation or the VIRAGE trial. Photo: National Cancer Institute / Unsplash.
Leave a Reply